Topline results were announced from a phase 3 study evaluating secukinumab in adults with newly diagnosed or relapsing giant cell arteritis (GCA). Secukinumab is an interleukin-17A antagonist ...

The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) ...

Basel, July 03, 2025 - Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell ...

secukinumab, 300 mg every 4 weeks secukinumab, 300 mg every 2 weeks Most differences between adalimumab 40 mg once per week and other targeted treatments did not show statistical significance.

The Novartis drug was being evaluated as a potential treatment for giant cell arteritis (GCA), which is the most common form of systemic vasculitis. Vasculitis is an autoimmune disorder that leads ...

Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab) 1 Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study ...

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

In a network meta-analysis of 25 randomized trials, sonelokimab was ranked highest for treating patients with moderate-to-severe hidradenitis suppurativa (HS). Adalimumab, lutikizumab, and ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Home NICE Guidance Conditions and diseases Musculoskeletal conditions Hip conditions Secukinumab for treating relapsed polymyalgia rheumatica [ID6599] Awaiting development [GID-TA11806] Expected ...